PharmaMar has requested the process of re-examination for Aplidin® from

(Pharmamar) PharmaMar has announced the initiation of the re-examination process by the European Medicines Agency for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.

PharmaMar has requested the process of re-examination for Aplidin® from the EMA

Related Posts

Sleep Quality Links Synergistically with Frailty to Increase Cardiometabolic Multimorbidity in Elderly Chinese

Cognitive reserve helps older adults resist frailty and recover better

Physical Activity and Health Inequality in China’s Older Adults

Topological Jackiw-Rebbi States in Photonic Van der Waals Heterostructures

POPULAR NEWS

Groundbreaking Discovery: New Shark Species Identified for the First Time

Controlled Study Defines Pediatric Long COVID Features

Behavioral Nudge Boosts Medication Prescriptions for Alcohol Reduction

Clean Cooking and Remittances Slash Somalia’s Ecological Footprints

About

Follow us

Recent News

Sleep Quality Links Synergistically with Frailty to Increase Cardiometabolic Multimorbidity in Elderly Chinese

Cognitive reserve helps older adults resist frailty and recover better

Physical Activity and Health Inequality in China’s Older Adults

Subscribe to Blog via Email

Welcome Back!

Retrieve your password